Cantor Fitzgerald Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price

Nyxoah (NASDAQ:NYXH) had its price objective dropped by stock analysts at Cantor Fitzgerald to $6.00 in a research note issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 270.37% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Piper Sandler reissued an “overweight” rating and issued a $6.00 target price (down from $7.00) on shares of Nyxoah in a research report on Thursday, August 6th. Robert W. Baird set a $2.31 target price on Nyxoah in a research report on Thursday, August 6th. Weiss Ratings cut shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. Wall Street Zen cut shares of Nyxoah from a “hold” rating to a “sell” rating in a report on Sunday, August 9th. Finally, Stifel Nicolaus reduced their price objective on Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, June 17th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.26.

Nyxoah Price Performance

Shares of NYXH stock opened at $1.62 on Monday. The stock’s fifty day moving average price is $1.55 and its 200 day moving average price is $2.82. Nyxoah has a 1-year low of $1.26 and a 1-year high of $6.87. The company has a market cap of $62.79 million, a price-to-earnings ratio of -0.64 and a beta of 1.62. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.38 and a quick ratio of 2.31.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.20). The business had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $8.64 million. Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%. On average, research analysts expect that Nyxoah will post -1.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nyxoah

Several hedge funds and other institutional investors have recently modified their holdings of NYXH. Heights Capital Management Inc. acquired a new stake in shares of Nyxoah in the fourth quarter valued at approximately $3,575,000. Deutsche Bank AG increased its position in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after purchasing an additional 10,000 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Nyxoah in the 3rd quarter valued at approximately $98,000. Bank of America Corp DE raised its position in Nyxoah by 152.7% in the third quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock valued at $91,000 after purchasing an additional 12,012 shares during the period. Finally, Raymond James Financial Inc. raised its holdings in shares of Nyxoah by 35.6% in the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after buying an additional 3,353 shares during the period.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep?disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.